MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagylysosomal pathway in acute promyelocytic leukemia

Autophagy

Volumn 10, Issue 10, 2014, Pages 1726-1737

  Zeng, Cheng Wu ^a   Chen, Zhen Hua ^a   Zhang, Xing Ju ^a   Han, Bo Wei ^a   Lin, Kang Yu ^a   Li, Xiao Juan ^a   Wei, Pan Pan ^a   Zhang, Hua ^b   Li, Yangqiu ^c   Chen, Yue Qin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Autophagy; Degradation; Leukemia; microRNA; PML RARA

Indexed keywords

DNA; DNA DAMAGE REGULATED AUTOPHAGY MODULATOR 2; HYBRID PROTEIN; MICRORNA; MICRORNA 125B1; ONCOPROTEIN; PML RARA PROTEIN; RETINOIC ACID; TRANSCRIPTOME; UNCLASSIFIED DRUG; DRAM2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MIRN125 MICRORNA, HUMAN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BONE MARROW CELL; CELL DIFFERENTIATION; CHILD; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYSOSOME; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; INFANT; METABOLISM; MOLECULAR GENETICS; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHAGOSOME; PRESCHOOL CHILD; TUMOR CELL LINE; ULTRASTRUCTURE;

ADOLESCENT; ANIMALS; AUTOPHAGY; BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYSOSOMES; MALE; MEMBRANE PROTEINS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PHAGOSOMES; PROTEOLYSIS; TRETINOIN;

EID: 84907903396     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.29592     Document Type: Article

References (41)

1. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167-215; PMID:10233871
2. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66:675-84; PMID:1652369; http://dx.doi.org/10.1016/0092-8674(91)90113-D
3. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-72; PMID:3165295
4. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981; 57:1000-4; PMID:6939451
5. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14:1333-42; PMID:19029980; http://dx.doi.org/10.1038/nm.1891
6. Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de Thé H. Retinoic acid induces proteasomedependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 1999; 96:14807-12; PMID:10611294; http://dx.doi.org/10.1073/pnas.96.26.14807
7. Isakson P, Bjøra˚s M, Bøe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010; 116:2324-31; PMID:20574048; http://dx.doi.org/10.1182/blood-2010-01-261040
8. Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy 2011; 7:401-11; PMID:21187718; http://dx.doi.org/10.4161/auto.7.4.14397
9. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290:1717-21; PMID:11099404; http://dx.doi.org/10.1126/science.290.5497.1717
10. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
11. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328:240-3; PMID:20378816; http://dx.doi.org/10.1126/science.1183424
12. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292:1552-5; PMID:11375494; http://dx.doi.org/10.1126/science.292.5521.1552
13. Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, Wan X. MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 2011; 11:425; PMID:21970405; http://dx.doi.org/10.1186/1471-2407-11-425
14. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205:2499-506; PMID:18936236; http://dx.doi.org/10.1084/jem.20080285
15. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23:862-76; PMID:19293287; http://dx.doi.org/10.1101/gad.1767609
16. Zeng CW, Zhang XJ, Lin KY, Ye H, Feng SY, Zhang H, Chen YQ. Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways. Mol Pharmacol 2012; 81:578-86; PMID:22252650; http://dx.doi.org/10.1124/mol.111.076794
17. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111:5078-85; PMID:18337557; http://dx.doi.org/10.1182/blood-2008-01-133355
18. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008; 105:3945-50; PMID:18308931; http://dx.doi.org/10.1073/pnas.0800135105
19. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One 2009; 4:e7826; PMID:19915715; http://dx.doi.org/10.1371/journal.pone.0007826
20. Walter MJ, Park JS, Ries RE, Lau SK, McLellan M, Jaeger S, Wilson RK, Mardis ER, Ley TJ. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proc Natl Acad Sci U S A 2005; 102:12513-8; PMID:16113082; http://dx.doi.org/10.1073/pnas.0504247102
21. Chapiro E, Russell LJ, Struski S, Cavé H, Radford-Weiss I, Valle VD, Lachenaud J, Brousset P, Bernard OA, Harrison CJ, et al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010; 24:1362-4; PMID:20485370; http://dx.doi.org/10.1038/leu.2010.93
22. Ward SV, Sternsdorf T, Woods NB. Targeting expression of the leukemogenic PML-RARα fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosis. Hum Gene Ther 2011; 22:1593-8; PMID:21846246; http://dx.doi.org/10.1089/hum.2011.079
23. Kamashev D, Vitoux D, De Thé H. PML-RARARXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 2004; 199:1163-74; PMID:15096541; http://dx.doi.org/10.1084/jem.20032226
24. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5:621-8; PMID:18516045; http://dx.doi.org/10.1038/nmeth.1226
25. Yu L, Zhang YD, Zhou J, Yao DM, Li X. Identification of target genes of transcription factor CEBPB in acute promyelocytic leukemia cells induced by all-trans retinoic acid. Asian Pac J Trop Med 2013; 6:473-80; PMID:23711709; http://dx.doi.org/10.1016/ S1995-7645(13)60077-2
26. Yu M, Tong JH, Mao M, Kan LX, Liu MM, Sun YW, Fu G, Jing YK, Yu L, Lepaslier D, et al. Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes. Proc Natl Acad Sci U S A 1997; 94:7406-11; PMID:9207104; http://dx.doi.org/10.1073/pnas.94.14.7406
27. Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M, et al. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 2010; 17:186-97; PMID:20159610; http://dx.doi.org/10.1016/j.ccr.2009.12.045
28. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28:27-30; PMID:10592173; http://dx.doi.org/10.1093/nar/28.1.27
29. Kitareewan S, Roebuck BD, Demidenko E, Sloboda RD, Dmitrovsky E. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 2007; 99:41-52; PMID:17202112; http://dx.doi.org/10.1093/jnci/djk004
30. Yoon JH, Her S, Kim M, Jang IS, Park J. The expression of damage-regulated autophagy modulator 2 (DRAM2) contributes to autophagy induction. Mol Biol Rep 2012; 39:1087-93; PMID:21584698; http://dx.doi.org/10.1007/s11033-011-0835-x
31. Walter MJ, Park JS, Lau SK, Li X, Lane AA, Nagarajan R, Shannon WD, Ley TJ. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol 2004; 24:10882-93; PMID:15572690; http://dx.doi.org/10.1128/MCB.24.24.10882-10893.2004
32. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A 2010; 107:14235-40; PMID:20660734; http://dx.doi.org/10.1073/pnas.1009798107
33. Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Luchetti L, Masella B, Morsilli O, Pelosi E, Samoggia P, et al. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000; 96:1531-7; PMID:10942402
34. Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ, Tong JH, Lanotte M, Waxman S, Chen SJ, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96:1496-504; PMID:10942397
35. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000; 5:821-30; PMID:10882118; http://dx.doi.org/10.1016/S1097-2765(00)80322-6
36. O'Prey J, Skommer J, Wilkinson S, Ryan KM. Analysis of DRAM-related proteins reveals evolutionarily conserved and divergent roles in the control of autophagy. Cell Cycle 2009; 8:2260-5; PMID:19556885; http://dx.doi.org/10.4161/cc.8.14.9050
37. Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, Cui Z, Zhang J, Yi K, Xu W, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 2012; 22:806-21; PMID:22349460; http://dx.doi.org/10.1038/cr.2012.30
38. Chen S, Yang P, Jiang F, Wei Y, Ma Z, Kang L. De novo analysis of transcriptome dynamics in the migratory locust during the development of phase traits. PLoS One 2010; 5:e15633; PMID:21209894; http://dx.doi.org/10.1371/journal.pone.0015633
39. Audic S, Claverie JM. The significance of digital gene expression profiles. Genome Res 1997; 7:986-95; PMID:9331369
40. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27:3650-8; PMID:19506161; http://dx.doi.org/10.1200/JCO.2008.20.1533
41. Zhang SY, Zhu J, Chen GQ, Du XX, Lu LJ, Zhang Z, Zhong HJ, Chen HR, Wang ZY, Berger R, et al. Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice. Blood 1996; 87:3404-9; PMID:8605358